Affiliation:
1. University Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad
Abstract
Introduction. Tumor lysis syndrome is an emergency condition requiring prompt
recognition and treatment. It?s a consequence of spontaneous or
therapy-induced cellular death leading to the release of intracellular ions
and metabolic products of purine bases into the bloodstream.
Pathophysiology. The characteristic metabolic derangement comprises
hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. These
metabolic changes can lead to kidney failure, arrhythmia, and seizures.
Epidemiology, classification and risk assessment. The incidence of tumor
lysis syndrome varies between different types of tumors, but it is most
common in hematologic malignancies. According to Cairo - Bishop
Classification, tumor lysis syndrome can be defined as laboratory tumor
lysis syndrome and clinical tumor lysis syndrome. Preventive measures and
treatment of tumor lysis syndrome. Frequent laboratory monitoring is
obligatory in patients with intermediate and high risk of tumor lysis
syndrome. Preventive measures are based on vigorous hydration and
administration of medication to control serum uric acid levels. When
clinical tumor lysis syndrome develops, additional treatment, including
renal replacement therapy, is needed for the correction of metabolic
disturbances. Conclusion. Tumor lysis syndrome is a potentially fatal
complication in patients with suffering from malignancies. Early recognition
of patients at risk and administration of prophylactic and therapeutic
measures improves outcomes for these patients.
Publisher
National Library of Serbia